CYP19A1 and breast cancer: Aspirin, a non-steroidal anti-inflammatory drug (NSAID), has been extensively studied for breast cancer prevention due to its inhibition of COX-2 and downstream effects on inflammation, aromatase activity, and estrogen biosynthesis.